Abstract
Background and Aims
Most facets of Inflammatory Bowel Disease (IBD) have not been thoroughly compared
among minority populations, including Black patients. Our study was designed to characterize
the demographics, phenotypes, outcomes, healthcare utilization, and treatment of IBD
in a large cohort with 38% Black patients.
Methods
Electronic health records of 3272 IBD patients seen in a tertiary academic medical
network from 2012 to July 15th, 2019 were analyzed.
Results
Black patients with Crohn's disease were significantly more likely than White patients
to suffer from perianal (p < 0.001), fistulizing (p < 0.001), and fibrostenotic phenotypes (p < 0.001). Black patients with IBD were significantly more likely to undergo IBD-related
surgery (p = 0.042) and experience an IBD-related complication (p < 0.001). The proportion of patients with at least one colonoscopy, one visit to
the gastroenterology clinic, one visit to the emergency department (ED), and one hospital
admission were higher in Black patients (p < 0.001, p = 0.005, p < 0.001, and p < 0.001; respectively).
Conclusions
Black IBD patients had more severe disease phenotypes and worse healthcare outcomes
than White patients. Black patients also used healthcare facilities and IBD medications
to an equal or greater extent, despite being of a lower average socioeconomic class
than their White counterparts. Our study suggests that underlying factors that do
not pertain to the utilization of healthcare resources may be responsible for these
worse outcomes in Black patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific.Am J Gastroenterol. 2019; 114: 107-115
- Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review.Clin Gastroenterol Hepatol. 2020; 18: 304-312
- The global burden of IBD: from 2015 to 2025.Nat Rev Gastroenterol Hepatol. 2015; 12: 720-727
- Racial and ethnic minorities with inflammatory bowel disease in the United States: a systematic review of disease characteristics and differences.Inflamm Bowel Dis. 2016; 22: 2023-2040
- Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010.Therap Adv Gastroenterol. 2019; 121756284819827692
- Prevalence of inflammatory bowel disease among Medicare fee-for-service beneficiaries - United States, 2001-2018.MMWR Morb Mortal Wkly Rep. 2021; 70: 698-701
- Inflammatory bowel disease in African Americans.Inflamm Bowel Dis. 2003; 9: 380-385
- Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 Through 2010.Clin Gastroenterol Hepatol. 2017; 15: 857-863
- The current state of care for Black and Hispanic inflammatory bowel disease patients [published online ahead of print, 2022 Jul 11].Inflamm Bowel Dis. 2022;
- Minority representation in clinical trials in the United States: trends over the past 25 years.Mayo Clin Proc. 2021; 96: 264-266
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis [published online ahead of print, 2022 Jul 30].Gut. 2022;
- Race and fistulizing perianal Crohn's disease.J Clin Gastroenterol. 2015; 49: e21-e23
- Infliximab for the treatment of fistulas in patients with Crohn's disease.N Engl J Med. 1999; 340: 1398-1405
- Infliximab maintenance therapy for fistulizing Crohn's disease.N Engl J Med. 2004; 350: 876-885
- Racial disparities in utilization of specialist care and medications in inflammatory bowel disease.Am J Gastroenterol. 2010; 105: 2202-2208
- Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study.Inflamm Bowel Dis. 2008; 14: 13-19
United States Census Bureau. 2019 American community survey demographic and housing 1-year estimates. Released September 17, 2020. Accessed January 5, 2021.
“Hospitals and Clinics.” https://umc.edu/Healthcare/Patients-and-Visitors/Hospitals%20and%20Clinics.html. Accessed January 1, 2022.
United States Census Bureau. 2013-2018 American community survey selected economic characteristics 5-year estimates data profiles. Released December 19, 2019. Accessed July 6, 2020.
- Crohn's disease in an African-American population.Am J Med Sci. 2008; 336: 389-392
- Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies.Clin Gastroenterol Hepatol. 2018; 16 (e11): 190-197
- Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort.Am J Gastroenterol. 2006; 101: 1012-1023
- Lack of difference in treatment patterns and clinical outcomes between black and white patients with inflammatory bowel disease.Inflamm Bowel Dis. 2018; 24: 2634-2640
- Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases.Gastroenterology. 2021; 160: 677-689
- Racial disparities in surgical outcomes of patients with Inflammatory Bowel Disease.Am J Surg. 2018 Jun; 215: 1046-1050
- Racial disparities exist in surgical outcomes for patients with inflammatory bowel disease.Am J Surg. 2021 Apr; 221: 668-674
- Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness.Inflamm Bowel Dis. 2013 Mar; 19: 627-643
- Disease presentation and clinical course in black and white children with inflammatory bowel disease.J Pediatr Gastroenterol Nutr. 2007; 44: 555-560
- Top-down therapy for IBD: rationale and requisite evidence.Nat Rev Gastroenterol Hepatol. 2010; 7: 86-92
- Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease.Inflamm Bowel Dis. 2009; 15: 1233-1239
- Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey.Inflamm Bowel Dis. 2011; 17: 1270-1276
- Patient nonadherence to medication in inflammatory bowel disease.Am J Gastroenterol. 2003; 98: 1535-1544
- Predictors of medication adherence in inflammatory bowel disease.Am J Gastroenterol. 2007; 102: 1417-1426
- Correlates of anemia in American blacks and whites: the REGARDS Renal Ancillary Study.Am J Epidemiol. 2009; 169: 355-364
- Clinical Manifestations of Crohn's Disease in African Americans in a Rural versus Urban Setting [Abstract].Am J Gastroenterol. 2021; 116: S421-S422
Analytics, University of Mississippi Medical Center, Center for Informatics and Analytics. Patient Cohort Explorer (PCE). Released May 6, 2020. Accessed September 5.
Article info
Publication history
Accepted:
February 20,
2023
Received:
October 15,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.
